CD8A and neoplasm: To put the TME-Analyzer to the test, we imaged tumor border and center regions with Multiplexed immunofluorescence (MxIF) in whole slide sections of 63 primary TNBC patients and assessed the presence of CD3, CD8, CD20, CD56, CD68 and pan-Cytokeratin (CK)-positive cells.